TTY Biopharm Company Limited (4105.TWO)

TWD 72.7

(-0.41%)

Market Cap (In TWD)

18.07 Billion

Revenue (In TWD)

5.5 Billion

Net Income (In TWD)

1.12 Billion

Avg. Volume

418.61 Thousand

Currency
TWD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
69.5-83.0
PE
-
EPS
-
Beta Value
0.189
ISIN
TW0004105002
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Kuo-Chiang Chang
Employee Count
-
Website
https://www.tty.com.tw
Ipo Date
2007-12-31
Details
TTY Biopharm Company Limited, together with its subsidiaries, engages in the development and sale of pharmaceutical and chemical drugs in Taiwan and internationally. The company operates through Oncology Business Unit, Intensive Care Business Unit, Healthcare Business Unit, Export and CDMO Business Unit, and Other Business Unit segments. It offers oncology drugs under the Lipo-Dox, Lonsurf, UFUR, TS-1, Pexeda, Gemmis, Oxalip, Irino, Epicin, Tynen, Anazo, Folina, Thado, Andason, Ivic, Asadin, Leavdo, Painkyl, Megest, Episil, Otril, Zobonic, Yondelis, and Pemazyre names for anti-cancer and supplementary treatments. The company provides anti-infection drugs under the Brosym, Colimycin, Cubicin, Lipo-AB, Agrippal, Cepiro, Flusine, Maxtam, Metacin, and Flucelvax names for anti-infection and flu. In addition, it offers healthcare related drugs under the Algitab, Alginos, Alginos Fresh, Bio-Cal Plus, and Sulfin names for digest system, osteoporosis, and metabolism. Further, the company engages in the selling functional foods; and import and export trading and investment activities. The company was incorporated in 1960 and is headquartered in Taipei, Taiwan.